Bristol-Myers Squibb (BMY) PT Set at $58.00 by Credit Suisse Group

Credit Suisse Group set a $58.00 price objective on Bristol-Myers Squibb (NYSE:BMY) in a research note published on Tuesday morning. The firm currently has a hold rating on the biopharmaceutical company’s stock.

BMY has been the subject of a number of other reports. Vetr cut Bristol-Myers Squibb from a buy rating to a hold rating and set a $59.70 price objective for the company. in a research report on Friday, December 22nd. BMO Capital Markets set a $51.00 price target on Bristol-Myers Squibb and gave the stock a sell rating in a research note on Wednesday, February 14th. Zacks Investment Research lowered Bristol-Myers Squibb from a hold rating to a sell rating in a research note on Monday, January 29th. TheStreet lowered Bristol-Myers Squibb from a b rating to a c+ rating in a research note on Thursday, March 8th. Finally, Morgan Stanley lowered Bristol-Myers Squibb from an overweight rating to an equal weight rating and lifted their price target for the stock from $54.08 to $58.00 in a research note on Tuesday. Three research analysts have rated the stock with a sell rating, twelve have given a hold rating and nine have given a buy rating to the stock. The stock presently has a consensus rating of Hold and an average price target of $64.23.

How to Become a New Pot Stock Millionaire

Bristol-Myers Squibb stock opened at $51.17 on Tuesday. The company has a market capitalization of $84,257.61, a PE ratio of 17.00, a price-to-earnings-growth ratio of 1.39 and a beta of 0.96. Bristol-Myers Squibb has a 12 month low of $51.02 and a 12 month high of $70.05. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.55 and a quick ratio of 1.43.

Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Monday, February 5th. The biopharmaceutical company reported $0.68 EPS for the quarter, beating the Zacks’ consensus estimate of $0.67 by $0.01. The business had revenue of $5.45 billion during the quarter, compared to analysts’ expectations of $5.35 billion. Bristol-Myers Squibb had a return on equity of 35.43% and a net margin of 4.85%. The business’s revenue was up 3.9% compared to the same quarter last year. During the same period in the previous year, the business earned $0.63 earnings per share. equities analysts predict that Bristol-Myers Squibb will post 3.22 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, May 1st. Shareholders of record on Friday, April 6th will be paid a dividend of $0.40 per share. This represents a $1.60 dividend on an annualized basis and a yield of 3.13%. The ex-dividend date of this dividend is Thursday, April 5th. Bristol-Myers Squibb’s dividend payout ratio (DPR) is currently 53.16%.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in BMY. Delphi Private Advisors LLC acquired a new position in Bristol-Myers Squibb during the fourth quarter worth $108,000. Massey Quick Simon & CO. LLC boosted its stake in Bristol-Myers Squibb by 523.5% during the third quarter. Massey Quick Simon & CO. LLC now owns 1,777 shares of the biopharmaceutical company’s stock worth $113,000 after buying an additional 1,492 shares during the last quarter. NuWave Investment Management LLC acquired a new position in Bristol-Myers Squibb during the fourth quarter worth $119,000. Horan Capital Advisors LLC. acquired a new position in Bristol-Myers Squibb during the third quarter worth $122,000. Finally, AllSquare Wealth Management LLC acquired a new position in Bristol-Myers Squibb during the third quarter worth $134,000. 71.51% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION WARNING: This piece was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece on another publication, it was illegally stolen and reposted in violation of US & international copyright and trademark legislation. The correct version of this piece can be read at

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in the various therapeutic classes, such as oncology; cardiovascular; immunoscience; and virology, including human immunodeficiency virus (HIV) infection.

Analyst Recommendations for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with's FREE daily email newsletter.

Leave a Reply